Tecnimede Group

Bruno Ruas

Financial Leadership Steward

Motivation in Finance Leadership

One of my greatest drivers is the ability to contribute meaningfully to company growth— whether through the launch of new products or entry into new markets. Finance is no longer just a support function; it is now a catalyst for growth. It’s both challenging and exciting to assess the viability of new investments, analyze business models tailored to different geographies, or collaborate with innovation teams to develop solutions that address emerging needs in the pharmaceutical sector.

Another source of motivation is working with the new generation of professionals, whose mindset and approach often differ significantly from mine. This intergenerational interaction pushes me out of my comfort zone, challenges my leadership style, and encourages me to listen more. Working with young talent is a constant reminder that change is essential.

Finally, we are living in a time when Artificial Intelligence (AI) is profoundly transforming the pharmaceutical industry. From drug development to supply chain management and customer service, AI is no longer a future promise—it’s today’s reality. It is part of the CFO’s role to ensure that the organization adapts to these new work models, not only by assessing risks but also by identifying opportunities for automation, efficiency, and even reinvention of operational models.

This blend of strategy, transformation, human connection, and innovation is what continues to energize me.

Challenges for Pharma and Life Sciences Finance Leaders

The pharmaceutical and life sciences sector is undergoing a profound transformation, with significant implications for its financial structure. In the coming years, several emerging risks are expected to challenge the sustainability and competitiveness of companies, particularly small and mid-sized players.

One of the main concerns is the exponential increase in Research and Development (R&D) costs. The growing complexity of clinical trials, stricter regulatory requirements, and the shift toward innovative therapies—such as biologics and gene therapies—have made drug development increasingly expensive. This puts considerable pressure on budgets and can constrain innovation, especially for companies without strong financial backing.

"Finance is no longer just a support function; it is now a catalyst for growth."

Another critical factor is the gradual decline of the generics model, driven by a shrinking pipeline of expiring patents. For decades, patent expirations presented a significant opportunity for generics manufacturers to enter the market with lower-cost alternatives. However, as fewer high-impact patents approach expiry, this model is becoming less viable, forcing many companies to reassess their strategies.

At the same time, the sector is witnessing an increasing concentration of power among the so-called "Big Pharma"—companies with vastly superior financial, technological, and commercial capabilities. This concentration reinforces market entry barriers and makes it more difficult for smaller players to compete in both innovation and global distribution.

In such a demanding landscape, it will be essential to focus on specialized niche markets, where large pharmaceutical companies may not operate with the same agility. Here, differentiation can be achieved through proximity to patients, incremental innovation, and addressing unmet medical needs. Forming strategic partnerships—with research institutions, KOL´s, startups, or peer companies—can also serve as a key lever for sharing risk and accessing new knowledge and markets.

Additionally, value-added medicines present a promising opportunity. These are enhanced versions of existing medicines, through reformulation, combination, or improved delivery, that offer meaningful differentiation with lower development risks. They provide clear benefits to patients, such as improved adherence, reduced side effects, and greater convenience. In summary, financial sustainability in the pharma and life sciences sector will increasingly depend on strategic adaptability, intelligent niche positioning, and collaborative approaches that create tangible long-term value.

Aligning Financial Decisions with Long-Term Vision and Values

To ensure that financial decisions are aligned with the company’s long-term strategic vision, an integrated and dynamic approach to financial management is essential, one that connects future aspirations with today’s operational realities.

For a company committed to international expansion and the development of value-added medicines, this alignment becomes even more critical. These strategies require significant investment, long-term return horizons, and the ability to adapt to diverse market and regulatory environments.

Achieving this alignment means constant monitoring of short-term investments, ensuring that every decision made today contributes meaningfully to long-term goals. Clear financial and operational KPIs must be established to evaluate progress and to inform decisions on whether to continue, redirect, or discontinue projects.

Moreover, there must be flexibility built into financial models and investment plans. The ability to adjust the strategic path as conditions change is essential to mitigate risks associated with growth and maintain organizational resilience. This agility is particularly important when operating across multiple geographies or investing in incremental innovation, where patient-centric approaches and speed of execution are key.

The finance function must therefore evolve into a proactive, strategic enabler, not just a cost controller. It should support innovation, facilitate expansion and foster cross-functional collaboration. Promoting alignment between finance, commercial, and R&D teams is vital to ensure that all decisions—regardless of timeframe— support the company’s future positioning.

Furthermore, a company’s core values must be actively upheld. Simply publishing them in documents is not enough. They must be lived and embedded in the company culture in a consistent and authentic way. Human Resources plays a key role here, not only in promoting these values but in continuously monitoring cultural alignment across the workforce. This includes behavioral assessments, structured feedback, and identifying signs of misalignment. When it becomes clear that individuals—regardless of technical skill—are not aligned with the organization’s values, replacement or reallocation should be considered. Retaining those who undermine the culture damages team morale, erodes leadership credibility, and weakens the company’s collective purpose. Protecting values requires courage, consistency, and disciplined talent management.